Iron chelation is lifelong therapy — and since generic deferasirox arrived at roughly 92% below brand price, almost nobody should be paying brand rates. We make sure you’re on the right version at the right price, and manage every program for a flat $69.95 per month.
For deferasirox in 2026, the honest first move isn’t an application — it’s a substitution check. Generic deferasirox tablets (the Jadenu-equivalent) and dispersible tablets (the Exjade-equivalent) are marketed by more than ten manufacturers at roughly 92% below brand, stocked widely, and sold through channels as simple as Cost Plus Drugs. For the minority who need brand — a documented formulation response, a granule formulation question for a child, a plan quirk — two Novartis programs exist: the Oncology Universal Co-Pay Program ($25 per fill, up to $15,000 a year, commercial insurance only) and the Novartis Patient Assistance Foundation (1-800-277-2254; free medication for income-eligible uninsured and government-insured patients — noting the 2025 rule changes: commercial insurance disqualifies, and low-income Part D applicants need an Extra Help denial first). Applying anywhere is free. Iron overload is managed for years and monitored by ferritin labs, so the money question compounds annually. For a flat $69.95 per month, our Patient Advocates get the version right, the price right, and every renewal filed on time.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens (brand) | ~$8,200 | Save substantially |
| CVS Pharmacy (brand) | ~$8,500 | Save substantially |
| Walmart (brand) | ~$5,300 | Save substantially |
| Costco (brand) | ~$5,200 | Save substantially |
Generic deferasirox FC | ~$1,500 | Generic — lower |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
Every route above is free to use directly. Our $69.95/month service covers full advocacy — the substitution check, the program filings when brand is warranted, and renewals kept current across the whole regimen, which for transfusion-dependent patients is rarely one drug.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Jadenu:
Still $5,000–$8,500 per month even with the best discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Jadenu assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Deferasirox is an oral iron chelator — it binds the excess iron that accumulates from repeated blood transfusions and carries it out of the body, protecting the heart and liver from iron’s slow damage.
How Deferasirox Works:
Every transfused unit of blood delivers iron the body cannot excrete on its own. Over dozens of transfusions — the reality of thalassemia, sickle cell disease, and MDS — iron loads into the liver, heart, and endocrine organs, where it is quietly toxic. Deferasirox binds that iron selectively so it leaves in bile and stool, and daily use keeps ferritin trending down. It replaced nightly infusion pumps (deferoxamine) as the standard for most patients — an enormous quality-of-life win that generic pricing has now made affordable too.
Form and Use:
Once daily, dosed by body weight and adjusted against ferritin labs. Three formulations exist and matter: film-coated tablets swallowed whole with or without food (the Jadenu style — simplest), dispersible tablets stirred into liquid on an empty stomach (the older Exjade style), and granules for children. All are genericized except some granule presentations; the tablet generic is the default. Chelation is a marathon — adherence gaps show up in ferritin months later, which is why cost structure matters more than any single fill.
Generic Availability:
Among the deepest generic markets in specialty medicine: ten-plus manufacturers since 2019 across strengths and formulations, with cash prices around 92% below brand and availability through mainstream and direct-to-consumer channels including Cost Plus Drugs. Pharmacists substitute automatically unless brand is specified — and brand should be specified only for documented reasons.
Warnings:
Deferasirox carries boxed warnings for kidney injury (including failure), liver injury, and gastrointestinal bleeding — the reason for scheduled creatinine, liver-enzyme, and ferritin monitoring, and for dose pauses when labs drift. Hydration matters; NSAIDs and other nephrotoxic drugs compound risk. Report decreased urination, jaundice, black stools, or severe abdominal pain immediately. Hearing and vision checks are part of long-term monitoring.
Generic: roughly $141 (90 mg), $284 (180 mg), or $553 (360 mg) per 30 tablets. Brand Jadenu: $1,784 to $7,113 for the same. Weight-based dosing multiplies both. The generic substitution is the single biggest saving in this entire category; our $69.95 monthly fee covers making sure it actually happens, and layering programs on top when needed.
Yes — AB-rated, marketed since 2019 by ten-plus manufacturers, substitutable at the counter. The formulations differ from each other (tablets vs. dispersible vs. granules), but within a formulation, generic and brand are equivalents.
Yes — under Part D, with generic-tier copays for most and the $2,100 annual cap (2026) as backstop. Income-eligible Medicare patients who need brand can apply to the Novartis foundation — with the 2025 rule that low-income Part D applicants first need an Extra Help denial letter.
No — commercial insurance only. Medicare patients rely on generic pricing, the Part D cap, Extra Help, or the foundation.
The dispersible-tablet original was largely supplanted by Jadenu (film-coated tablets) years ago, and generics now cover both formulations. Whether brand Exjade remains shipping matters little — the generic dispersible tablets fill the same prescriptions.
Granule presentations are the one corner with less generic coverage — some strengths remain brand-only. That’s the legitimate brand-assistance case: the co-pay program or foundation applies, and we file it while checking whether a tablet or dispersible generic is age-appropriate yet.
Denials are usually about documentation — income proof, the Extra Help letter, or insurance-status mismatches under the 2025 rules. Applications can be corrected and resubmitted — and generic pricing means nobody goes unchelated while an appeal runs. We review the denial letter, fix what triggered it, and resubmit.
Lifelong chelation at brand prices is a six-figure decade; at generic prices it’s a manageable line item — and the difference is one substitution plus the right program behind it. Check your eligibility today; the pre-qualification review is free, and if we can’t help you, you pay nothing.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.